Bio-Techne (NasdaqGS:TECH) FY Conference November 18, 2025 09:00 AM ET Company ParticipantsJim Hippel - VP and CFOWill Geist - President of Protein SciencesModeratorIntend to be more of a fireside chat, so I'll stop along the way and pull for any questions, so feel free to chime in as needed. With that, I'll turn it over to you all for any opening comments that you want to make, and we'll launch into Q and A.Jim HippelYeah, sure. Thank you, Mac. It's always a pleasure to be here. Stephen's always one of my ...

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics. ...

Core Insights - The report provides a comprehensive analysis of global biologics sales, including various categories such as cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, and RNA-based drugs [1][3][5] - It highlights sales data, growth trends, and rankings of top biologics, making it essential for biopharma professionals, investors, and market analysts [1][2] Sales Data Overview - The report compiles and analyzes sales data for originator recombinant therapeutic proteins and antibodies for the year 2024, including publicly available data for biosimilars and new biologic modalities [3][5] - Sales data from 2012 to 2024 are summarized, showing growth rates and the percentage of antibody sales relative to total biologics sales [5] Product Categories - Individual product sales data are categorized into groups such as cancer antibodies, non-TNF anti-inflammatory mAbs, cardiometabolic antibodies, and more [9][10] - Target-specific sales data for cancer antibodies and non-TNF anti-inflammatory antibodies are calculated for 2024, covering various therapeutic areas [7][12] Market Trends - The report emphasizes the commercial success of novel antibody drug modalities, including antibody-drug conjugates and bispecific antibodies, with sales and growth rates presented from 2012 to 2024 [16] - A total of 75 innovator therapeutic antibodies and proteins achieved blockbuster status in 2024, each exceeding sales of US$ 1 billion [16] Company Rankings - A ranking list of the top 30 companies regarding biologics sales in 2024 is provided, along with company-specific sales data for biosimilars from 2020 to 2023 [16] - The report includes detailed sales data for various biologic products, highlighting the competitive landscape within the industry [14][16]